Conclusion
While Viagra has the most data for use within the female population, all PDE5-inhibitors (including Cialis and Levitra) work in a similar way and would be expected to have similar success or failure rates. The numerous conflicting studies regarding the success of PDE5-inhibitors in treating female sexual dysfunction suggests that the true nature of the dysfunction and underlying diseases play an important role in the success of these agents. Clearly defining patient characteristics and the underlying disorder in future studies, as well as establishing consistent methods of evaluating success, will help researchers determine the benefit of these agents for certain subsets of patients for treatment of sexual disorders.
Recommended Reading
Effect of Viagra, Cialis, and Levitra in Females With or Without Sexual Dysfunction
11 Facts About Osphena (ospemifene)
Osphena (ospemifene) Cost, Dosage, Side Effects, Uses, and Drug Interactions
Effect of Viagra, Cialis, and Levitra in Females With Various Conditions
Alternative Medicines for Menopause Symptoms
A Review of Contraceptives and Selecting A Method of Contraception
References
Spector IP, Carey MP. Review Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav. 1990 Aug; 19(4):389-408.
Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970.
Berman JR, Berman LA, Toler SM, et al; for the Sildenafil Study Group. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol. 2003;170(6 pt 1):2333-8.
Caruso S, Intelisano G, Lupo L, et al. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG. 2001;108:623-8.
Basson R, McInnes R, Smith MD, et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med. 2002;11:367-377.
Leddy LS, Yang CC, Stuckey BG, et al. Influence of sildenafil on genital engorgement in women with female sexual arousal disorder. J Sex Med. 2012;9(10):2693-7.
Caruso S, Rugolo S, Agnello C, et al. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril. 2006;85:1496-1501.
Alexander MS, Rosen RC, Steinberg S, et al. Sildenafil in women with sexual arousal disorder following spinal cord injury. Spinal Cord. 2011;49:273-9.
Dasgupta R, Wiseman OJ, Kanabar G, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol. 2004;171:1189-1193.
Nurnberg HG, Hensley PL, Heiman JR, et al. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA. 2008;300:395-404.
Salerian AJ, Deibler WE, Vittone BJ, et al. Sildenafil for psychotropic-induced sexual dysfunction in 31 women and 61 men. J Sex Marital Ther. 2000;26:133-140.
Nurnberg HG, Hensley PL, Gelenberg AJ, et al. Sildenafil for selective reuptake inhibitor associated female sexual dysfunction [abstract]. Presented at the 155th Annual Meeting of the American Psychiatric Association (APA); May 18-23, 2002; Philadelphia, PA.
Fava M, Rankin MA, Alpert JE, et al. An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. Psychother Psychosom 1998;67:328-331.
Caruso S, Intelisano G, Farina M, et al. The function of sildenafil on female sexual pathways: a double-blind, cross-over, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2003;110:201-206.
Data on File, Eli Lilly and Company and/or one of its subsidiaries; Obtained from Tadalafil Use in Females for Female Sexual Arousal Disorder (FSAD) or Lower Urinary Tract Symptoms [Standard Response Document], U.S. Medical Division, Lilly USA, LLC; 2014.
Caruso S, Cicero C, Romano M, et al. Tadalafil 5 mg daily treatment for type 1 diabetic premenopausal women affected by sexual genital arousal disorder. J Sex Med. 2012;9(8):2057-2065.
van der Made F , Bloemers J, van Ham D, et al. Childhood sexual abuse, selective attention for sexual cues and the effects of testosterone with or without vardenafil on physiological sexual arousal in women with sexual dysfunction: A pilot study . J Sex Med 2009;6(2):429-439.

Copyright 2026 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap